Can Fite Biopharma Ltd (CANF) Given a $6.00 Price Target at HC Wainwright

HC Wainwright set a $6.00 price objective on Can Fite Biopharma Ltd (NASDAQ:CANF) in a research report report published on Tuesday. The brokerage currently has a buy rating on the stock.

Separately, Maxim Group set a $7.00 price target on shares of Can Fite Biopharma and gave the company a buy rating in a research report on Wednesday, August 23rd.

Shares of Can Fite Biopharma (NASDAQ:CANF) traded up 2.1026% on Tuesday, reaching $1.5928. The company had a trading volume of 8,790 shares. The company’s market capitalization is $27.66 million. Can Fite Biopharma has a one year low of $1.50 and a one year high of $2.67. The company’s 50-day moving average is $1.68 and its 200-day moving average is $1.75.

COPYRIGHT VIOLATION NOTICE: “Can Fite Biopharma Ltd (CANF) Given a $6.00 Price Target at HC Wainwright” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/11/01/can-fite-biopharma-ltd-canf-given-a-6-00-price-target-at-hc-wainwright.html.

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

What are top analysts saying about Can Fite Biopharma Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Can Fite Biopharma Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit